Climb Bio, Inc. (CLYM) vs Faeth Therapeutics, Inc. (FTH)

A side-by-side comparison of Climb Bio, Inc. and Faeth Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Climb Bio, Inc. logo
CLYM
Climb Bio, Inc.
$626M
$10.93HealthcareDelayed quote: Oct 6, 2026, 10:45 AM EDT
Faeth Therapeutics, Inc. logo
FTH
Faeth Therapeutics, Inc.
$679M
$26.34HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT

Total return — CLYM vs FTH

growth of $100 · dividends reinvested · last 2y
CLYM +41.1% (+18.8%/yr)FTH +122.5% (+49.2%/yr)FTH compounded faster over this window
0100200300Start $10020252026$141$222
CLYM FTH

CLYM vs FTH: by the numbers

  • •FTH is the larger company ($679M vs $626M market cap).

Metrics side by side

Valuation

MetricCLYMFTH
P/B ratio2.613.93

Profitability

MetricCLYMFTH
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-24.06%-113.05%
ROIC-26.94%-110.62%

Growth (annualized)

MetricCLYMFTH
Total return CAGR (5Y)N/A-31.75%

Go deeper

Full CLYM analysisFull FTH analysisInteractive comparison tool

Dig into the metrics

Climb Bio ROEFaeth Therapeutics ROEClimb Bio operating marginFaeth Therapeutics operating marginClimb Bio revenue growthFaeth Therapeutics revenue growthClimb Bio free cash flowFaeth Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.